598 results on '"immunosuppressed"'
Search Results
2. Wind Ensemble Infectious Disease Risks: A Microbiological Examination of the Fungal Flora in the Water Key Liquids of Brass and Woodwind Instruments.
- Author
-
Johnston, Samantha, Mobley, James, Bridges, Cynthia, and Torres, Margarito
- Subjects
- *
WOODWIND instruments , *BRASS instruments , *WIND instrument players , *WIND instruments , *BANDS (Musical groups) - Abstract
Background: When played, wind instruments are warmed from room temperature to body temperature. Condensation accumulates within the instrument the longer it is played and will need to be expelled to maintain tone quality. Brass instruments, except French horns, have water keys while woodwind instruments, except some saxophone models, must manually be cleared of accumulated condensate. Usually this is done by emptying the liquids onto the rehearsal floor. The purpose of this study was to determine whether the condensate released from band instruments contains fungal flora that could potentially pose a health risk to players in a wind ensemble. Methods: Fluid swabs were obtained from a total of 59 woodwind and brass instruments after being played until warm. The swabs were processed as environmental specimens at Clinical Pathology Laboratories, Austin, Texas. The results were compiled and analyzed based on instrument and ensemble. The data were further examined detailing total fungal growth per ensemble and fungal growth per instrument. A Fisher's Exact Test in a 2x3 contingency table was calculated to evaluate the significance of the data. Results: There were three mold species identified from 26 of the total cultured instruments, with Paecilomyces and Fusarium species predominating. Four yeast species were identified from 14 of the total cultured instruments, with Candida species predominating. The remaining 27 instruments yielded no microbial growth. Conclusion: While fungal growth is present in the condensate released by instruments, the recovered species do not pose a significant health risk to immunocompetent musicians. Musicians who are immunocompromised or who have chronic medical conditions may rarely be vulnerable to infections from contaminated instruments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
3. Hepatitis E virus immunosuppressed animal models.
- Author
-
Yadav, Kush Kumar and Kenney, Scott P.
- Subjects
- *
HEPATITIS E virus , *CHRONIC active hepatitis , *HIV-positive persons , *IMMUNOCOMPROMISED patients , *ANIMAL species - Abstract
Hepatitis E virus (HEV) is an important emerging pathogen producing significant morbidity in immunosuppressed patients. HEV has been detrimental to solid organ transplant (SOT) patients, cancer patients, and HIV-positive patients, where chronic HEV infections occur. Blood-borne transfusions and multiple cases of chronic HEV infection in transplant patients have been reported in the past few decades, necessitating research on HEV pathogenesis using immunosuppressed animal models. Numerous animal species with unique naturally occurring HEV strains have been found, several of which have the potential to spread to humans and to serve as pathogenesis models. Host immunosuppression leads to viral persistence and chronic HEV infection allows for genetic adaptation to the human host creating new strains with worse disease outcomes. Procedures necessary for SOT often entail blood transfusions placing immunosuppressive patients into a "high risk group" for HEV infection. This scenario requires an appropriate immunosuppressive animal model to understand disease patterns in these patients. Hence, this article reviews the recent advances in the immunosuppressed animal models for chronic HEV infection with emphasis on pathogenesis, immune correlates, and the liver pathology associated with the chronic HEV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Mucormicosis: estudio retrospectivo a 5 años en un hospital de tercer nivel de la Ciudad de México.
- Author
-
González Rivera, Carolina, González Ibarra, Misael, Duran Juárez, Sandra Edith, Hernández García, Jesús Guillermo, Guerrero del Moral, Bernardo, and Arenas Guzmán, Roberto
- Abstract
OBJECTIVE: To determine the incidence, risk factors, clinical findings and outcome of patients at Hospital Juarez of Mexico. MATERIALS AND METHODS: Retrospective, observational, cross-sectional, non-experimental, single-center and analytical study was done including the records of patients with direct examination, culture or histopathological study positive for mucormycosis. The incidence by year and demographic and clinical characteristics were studied from January 2017 to December 2022 at the Hospital Juarez of Mexico. RESULTS: A total of 14 patients with mucormycosis were identified. The median age was 51 years, and the majority were women (n = 9). The site of involvement was rhinoorbito-cerebral mucormycosis in the entire sample. Eleven patients had uncontrolled diabetes mellitus. Annual cases of mucormycosis increased notably at the end of the COVID-19 pandemic during 2022. CONCLUSIONS: Mucormycosis is an invasive fungal disease most seen in immunocompromised patients. In this study, its highest prevalence was in decompensated diabetes mellitus and the clinical variety was rhino-orbito-cerebral. An increase was noted at the end of the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Epidemiology, Clinical Manifestations, Treatment, and Outcome of Mucormycosis: A Review of 77 Cases From a Single Center in France.
- Author
-
Denis, Blandine, Resche-Rigon, Matthieu, Raffoux, Emmanuel, Ronchetti, Anne-Marie, Dudoignon, Emmanuel, Verillaud, Benjamin, Valade, Sandrine, Lorillon, Gwenaël, Rabian, Florence, Xhaard, Aliénor, Touratier, Sophie, Hamane, Samia, Alanio, Alexandre, and Castro, Nathalie De
- Subjects
- *
BLOOD diseases , *SYMPTOMS , *AMPHOTERICIN B , *MIXED infections , *POLYMERASE chain reaction , *MUCORMYCOSIS - Abstract
Background The aim of this study was to assess the epidemiology, clinical manifestations, and outcome of mucormycosis over 15 years in a single center in France. Methods We conducted a retrospective analysis of all mucormycosis cases in our institution from 1 January 2006 to 31 December 2020 and analyzed patients' medical records, laboratory results, and treatment to describe the epidemiology, clinical manifestations, diagnosis, treatment, and outcome. Mucorales quantitative polymerase chain reaction (qPCR) for the diagnosis was implemented in 2015. Results Seventy-seven mucormycosis cases were analyzed in 77 patients, with a median age of 54 years (60% male). Identified risk factors were hematological diseases (46 cases [60%]), solid malignancies (2 cases), solid organ transplants (3), burns (18), diabetes only (7), and trauma (1). Sites of infection were lungs (42%), sinus (36%), skin (31%), central nervous system (9%), liver (8%), others (6%), and disseminated (12%). Diagnosis remained difficult and qPCR contributed to mucormycosis diagnosis in 30% of cases. Among hematology patients, serum qPCR was the only positive test in 15% of cases. A mixed mold infection was diagnosed in 24 of 77 (31%) patients. Surgical treatment was undertaken in 43 (56%) cases. Most patients received liposomal amphotericin B (89%), with a combination therapy in 18 of 77 cases (23%). Three-month survival rate was 40% (95% confidence interval [CI],.30–.53]). As for treatment, adjunction of surgery (hazard ratio, 0.47 [95%CI,.25–.91); P = 0.02) was associated with lower mortality. Conclusions Mucormycosis remained associated with high mortality, especially in the hematological and burn populations. Surgery in combination with antifungal treatment was associated with improved survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Identification of Anncaliia algerae in Ascites in an Immunosuppressed Patient, China.
- Author
-
Wang, Zanzan, Li, Dan, Lu, Lingling, Xu, Zhijuan, Ouyang, Guifang, and Sun, Yongcheng
- Subjects
- *
ASCITIC fluids , *ACUTE myeloid leukemia , *VOCAL cords , *SYMPTOMS , *IMMUNOCOMPROMISED patients - Abstract
Anncaliia algerae , a microsporidium, has risen to prominence as an opportunistic pathogen, particularly afflicting individuals who are immunocompromised with conditions such as rheumatoid arthritis, organ transplantation, and hematologic malignancy. Surprisingly, despite its recognized impact, the identification of A algerae in ascitic fluid has not been documented. As such, we pinpointed A algerae as the probable instigator of ascitic accumulation in a patient with a history of acute myeloid leukemia and extended periods of immunosuppressive therapy. For this patient, there were no signs of A algerae –related infections (eg, myositis), vocal cord involvement, or disseminated infection. The presence of A algerae was finally identified by next-generation metagenomic sequencing analysis of the ascitic fluid. Clinical presentation was characterized by elevated C-reactive protein levels (110.7 mg/L), diminished platelet count (48 × 109/L), abdominal distension secondary to ascitic fluid accumulation, and lower limb pain, and it showed marked improvement following a 4-day regimen of sulfamethoxazole/trimethoprim and albendazole. Despite this promising response, the patient succumbed to aspiration of vomitus. This case underscores the importance of considering rarer organisms, such as A algerae infection, in patients who are immunocompromised and present with unexplained ascites accumulation. It highlights the potential effectiveness of sulfamethoxazole/trimethoprim and albendazole in managing such cases. Further research is warranted to elucidate optimal management strategies and improve outcomes in similar clinical scenarios. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Knowledge, Attitudes, and Practices Regarding Herpes Zoster Vaccination Among Specialists.
- Author
-
Singer, David, Sweeney, Carolyn, Stempniewicz, Nikita, Reynolds, Maria, Garbinsky, Diana, and Poston, Sara
- Subjects
- *
HERPES zoster , *IMMUNIZATION , *MEDICAL protocols , *POLICY sciences , *CROSS-sectional method , *MEDICAL specialties & specialists , *HEALTH attitudes , *RESEARCH funding , *GOVERNMENT agencies , *HEALTH policy , *VACCINATION , *MULTIPLE regression analysis , *DESCRIPTIVE statistics , *PROFESSIONS , *ATTITUDE (Psychology) , *ATTITUDES of medical personnel , *RECOMBINANT proteins , *HERPES zoster vaccines , *HEALTH promotion , *DATA analysis software , *MEDICAL practice , *IMMUNOCOMPETENCE , *IMMUNOSUPPRESSION , *GOVERNMENT regulation , *LEGAL compliance , *DISEASE risk factors - Abstract
Recombinant zoster vaccine has been recommended by the US Advisory Committee on Immunization Practices (ACIP) for the prevention of herpes zoster (HZ) in immunocompetent adults aged at least 50 years since 2018. In January 2022, this was extended to immunodeficient/immunosuppressed adults aged at least 19 years. Key study objectives were to assess specialists' knowledge of the ACIP HZ vaccination recommendations, their attitudes toward HZ vaccination, and HZ vaccination practices/barriers. This cross-sectional, web-based survey (conducted in March 2022) included US dermatologists, gastroenterologists, infectious disease specialists, oncologists, and rheumatologists who treat patients with psoriasis, inflammatory bowel disease, human immunodeficiency syndrome, solid tumors/hematological malignancies, and rheumatoid arthritis, respectively. Although most of the 613 specialists correctly identified the ACIP HZ vaccination recommendations for adults aged at least 50 years (84%) and immunodeficient/immunosuppressed adults aged at least 19 years (67%), only 29% knew that recombinant zoster vaccine is recommended for individuals who have previously received zoster vaccine live, and only 18% knew all current ACIP recommendations. For patients with the diseases listed, 84% of specialists thought that HZ is a serious risk, 75% that HZ vaccination is extremely/very important, and 69% were extremely/very likely to recommend HZ vaccination. Only 36% administer vaccines themselves, mainly because patients receive vaccinations from others. Barriers to vaccination included more urgent/acute issues, insufficient time, and lack of patient motivation/willingness. Full knowledge of the ACIP HZ vaccination recommendations among the surveyed specialists was low. There may be a need to educate specialists to improve adherence to these recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. An Unusual Case of Colitis in a Bone Marrow Transplant Patient.
- Author
-
Gupta, Nikita Y., Al Diffalha, Sameer, and Russ, Kirk B.
- Published
- 2024
- Full Text
- View/download PDF
9. Anti-Infection of Nasopharyngeal Carcinoma Combined with Non-Tuberculous Mycobacteria: A Case Report and Literature Review.
- Author
-
Li, Qinchuan, Guan, Wenju, Zhang, Jian, Chen, Min, and Zou, Ya
- Subjects
MYELOSUPPRESSION ,LITERATURE reviews ,NASOPHARYNX cancer ,SEPTIC shock ,COMPUTED tomography - Abstract
Background: Patients with nasopharyngeal carcinoma (NPC) combined with non-tuberculous Mycobacteria-pulmonary disease (NTM-PD) are very rare in the clinic, and our case is the first patient with NPC combined with NTM-PD. For oncologists, rapid control of the symptoms of infection is essential to the treatment of the primary disease. Case Presentation: A 58-year-old man who developed a NTM-PD after chemotherapy for nasopharyngeal carcinoma. Granulocytosis after chemotherapy is a major factor in the development of various infectious diseases. Nasopharyngeal tumor was found on MRI of the patient's head, and nasopharyngeal malignant tumor was considered after pathological examination after endoscopic resection of intranasal lesion, and then nasopharyngeal non-keratonic carcinoma (T4N1M0, stage IV) was confirmed in the department of oncology. The patient developed bone marrow suppression after chemotherapy and was admitted to hospital due to septic shock. Chest CT examination indicated pulmonary infection, and empirical antibiotic treatment was not effective. The NGS results showed that the patient was infected with Mycobacterium abscess. We treated with cefoxitin followed by moxifloxacin to reduce the lung lesions significantly. Conclusion: NPC with NTM-PD is very rare, and the treatment of NTM-PD is very important for the prognosis of the patient's primary disease. Our study provides experience for anti-infection treatment of patients with immunosuppression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. A rare case of disseminated pulmonary cryptococcosis in an immunocompetent patient
- Author
-
Hafisatu Gbadamosi, Jane Sandra Afriyie-Mensah, Emmanuel Nyamekye Ansah, Samuel Kwame Dadzie, and Peter Puplampu
- Subjects
Crptococcocus ,Immunocompetent ,Immunosuppressed ,Dissemination ,Pulmonary ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Pulmonary cryptococcosis is an uncommon invasive fungal infection of the lungs seen in immunocompromised individuals but increasingly reported among the immunocompetent. We report a rare case of pulmonary cryptococcosis in an immunocompetent host highlighting its unique clinical and radiological presentation. Clinical trial number: Not applicable.
- Published
- 2024
- Full Text
- View/download PDF
11. Hepatitis E virus immunosuppressed animal models
- Author
-
Kush Kumar Yadav and Scott P. Kenney
- Subjects
Hepatitis ,Humans ,Immunosuppressed ,Animal ,Models ,Chronic ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Hepatitis E virus (HEV) is an important emerging pathogen producing significant morbidity in immunosuppressed patients. HEV has been detrimental to solid organ transplant (SOT) patients, cancer patients, and HIV-positive patients, where chronic HEV infections occur. Blood-borne transfusions and multiple cases of chronic HEV infection in transplant patients have been reported in the past few decades, necessitating research on HEV pathogenesis using immunosuppressed animal models. Numerous animal species with unique naturally occurring HEV strains have been found, several of which have the potential to spread to humans and to serve as pathogenesis models. Host immunosuppression leads to viral persistence and chronic HEV infection allows for genetic adaptation to the human host creating new strains with worse disease outcomes. Procedures necessary for SOT often entail blood transfusions placing immunosuppressive patients into a “high risk group” for HEV infection. This scenario requires an appropriate immunosuppressive animal model to understand disease patterns in these patients. Hence, this article reviews the recent advances in the immunosuppressed animal models for chronic HEV infection with emphasis on pathogenesis, immune correlates, and the liver pathology associated with the chronic HEV infections.
- Published
- 2024
- Full Text
- View/download PDF
12. Therapeutic Role of HPV Vaccination on Benign HPV-induced Epithelial Proliferations in Immunocompetent and Immunocompromised Patients: Case Study and Review of the Literature.
- Author
-
Matucci-Cerinic, Caterina, Herzum, Astrid, Ciccarese, Giulia, Rosina, Silvia, Caorsi, Roberta, Gattorno, Marco, Occella, Corrado, Viglizzo, Gianmaria, and Volpi, Stefano
- Subjects
- *
LITERATURE reviews , *HUMAN papillomavirus vaccines , *SEXUALLY transmitted diseases , *HUMAN papillomavirus , *TREATMENT effectiveness , *WARTS , *GENITAL warts - Abstract
Human papillomavirus (HPV) vaccination represents a milestone in primary prevention of sexually transmitted infections. However, little is known about its possible effects on already established HPV infections. We report the case of a 9-year-old immunosuppressed girl with refractory warts, successfully treated with the nonavalent-HPV vaccine and review the literature about the therapeutic effects of HPV vaccination on benign HPV-induced epithelial proliferations in immunocompetent and immunosuppressed patients. In the literature, promising results were shown on cutaneous warts after HPV vaccination, especially in children and young adults, also in immunosuppressed patients, whereas controverse results were found on anogenital warts. These findings suggest a critical need for randomized clinical trials to assess the efficacy of HPV vaccination in the treatment of benign HPV-induced epithelial proliferations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.
- Author
-
Ng, Heng Joo, Alata, Maaz Kamal, Nguyen, Quang The, Huynh Duc Vinh, Phu, Tan, Jing Yuan, and Wong, Chieh Lee
- Subjects
- *
COVID-19 , *HEMATOLOGIC malignancies , *COVID-19 pandemic , *T cells , *DISEASE management - Abstract
Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. The clinical presentation and outcomes of COVID-19 in immunocompromised hosts in comparison to comorbid and immunocompetent patients: retrospective study of 384 cases.
- Author
-
Karimov, Ziya, Huseynova, Gunay, Kiris, Hakan Turan, Tongel, Cansu, Aliyeva, Aynur, Soyer, Nur, Abdullayeva, Nigar, Unat, Omer Selim, Basoglu, Ozen Kacmaz, Sayiner, Abdullah, and Tasbakan, Mehmet Sezai
- Subjects
COVID-19 pandemic ,IMMUNOCOMPROMISED patients ,MORTALITY ,HOSPITAL records ,HEALTH outcome assessment - Abstract
Copyright of Ege Journal of Medicine is the property of Ege University, Faculty of Medicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
15. Fractional commensurate model on COVID‐19 with microbial co‐infection: An optimal control analysis.
- Author
-
Vijayalakshmi, G. M., Roselyn Besi, P., and Akgül, Ali
- Subjects
MIXED infections ,COVID-19 ,COVID-19 pandemic ,SARS-CoV-2 Delta variant ,GLYCEMIC control - Abstract
Crossover behaviors have always existed in the history of infectious pandemics due to a few distinct, erratic spread outlines. This research aims to investigate the crossover behavior of the proposed SVICR commensurate fractional model for the COVID‐19 delta variant, considering microbial coinfections. A mathematical model in terms of Atangana–Baleanu Caputo (ABC) category fractional integrals takes into account the co‐infection of mucormycosis in immunocompromised COVID‐19 patients caused by microbial infections. ABC operators preserve the intact history of the happenings under contemplation through its nonsingular kernel. It is observed that the framed five‐compartmental SVICR model is positively bounded on R5, the solution space. Two equilibrium points E0andEe$$ {E}_0\mathrm{and}\ {E}_e $$ representing the survival and annihilation of sickness respectively are contributed by the single population N(t), which is counted in five dependent compartments: S(t),V(t),I(t),C(t),andR(t).$$ \mathrm{S}\left(\mathrm{t}\right),\mathrm{V}\left(\mathrm{t}\right),\mathrm{I}\left(\mathrm{t}\right),\mathrm{C}\left(\mathrm{t}\right),\mathrm{and}\ \mathrm{R}\left(\mathrm{t}\right). $$ The bilinear growth rate of new additional infections from the contagious infectives over time 't' is viewed through the threshold metric R0.$$ {R}_0. $$ Lyapunov's stability function examines the parametric influences over the virulent spread globally. The significant focus is to investigate the Mucormycosis cases in COVID‐19 patients with underlying diabetic complications. Diabetes mellitus is the major concern for several coinfections among COVID‐19 recoveries. Aiming to minimalize the critical states, an Lagrangian–Hamiltonian optimum control structure is also performed for the SVICR model by introducing control variables in effect to tri‐control probes of minimized contact rates, persuasive vaccinations, and glycemic control of post recovered diabetic patients. The hike in the Severity of the ailment due to fungal pathogens is studied through numerical convergence of predictor–corrector scheme and simulations. Using estimated parametric values from the statistical data of mucormycosis and infections of COVID‐19 reported cases in India, the prominence of control effects are visualized graphically. To conclude, a complete qualitative analysis of the minimization problem is executed for different levels of control values. We avow that effective control intrusions would almost certainly decline the complexities associated with the viral pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Impact of Immunosuppressed Status on Prognosis of Carbapenem-Resistant Organisms Bloodstream Infections
- Author
-
Yuan-Yuan Li, Yan Chen, Shan Li, Ran An, Xiao-Yun Hu, Wei Jiang, Chun-Yao Wang, Run Dong, Qi-Wen Yang, Li Weng, Jin-Min Peng, and Bin Du
- Subjects
Carbapenem-resistant organisms (CROs) ,Immunosuppressed ,Bloodstream infection (BSI) ,Mortality ,Antimicrobial therapy ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction The impact of immunosuppression on prognosis of carbapenem-resistant organism (CRO) bloodstream infection (BSI) remains unclear. The aim of this study was to clarify the relationship between immunosuppression and mortality of CRO-BSI and to identify the risk factors associated with mortality in immunosuppressed patients. Methods This retrospective study included 279 patients with CRO-BSI from January 2018 to March 2023. Clinical characteristics and outcomes were compared between the immunosuppressed and immunocompetent patients. The relationship between immunosuppression and 30-day mortality after BSI onset was assessed through logistic-regression analysis, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). Factors associated with mortality in immunosuppressed patients were analyzed using multivariable logistic regression analysis. Results A total of 88 immunocompetent and 191 immunosuppressed patients were included, with 30-day all-cause mortality of 58.8%. Although the 30-day mortality in immunosuppressed patients was significantly higher than in immunocompetent patients (46.6% vs. 64.4%, P = 0.007), immunosuppression was not an independent risk factor for mortality in multivariate logistic regression analysis (odds ratio [OR] 3.53, 95% confidence interval [CI] 0.74–18.89; P = 0.123), PSM (OR 1.38, 95% CI 0.60–3.18; P = 0.449,) or IPTW (OR 1.40, 95% CI 0.58–3.36; P = 0.447). For patients with CRO-BSI, regardless of immune status, appropriate antibiotic therapy was associated with decreased 30-day mortality, while Charlson comorbidity index (CCI), intensive care unit (ICU)-acquired infection and thrombocytopenia at CRO-BSI onset were associated with increased mortality. Conclusion Despite the high mortality rate of CRO-BSI, immunosuppression did not affect the mortality. Appropriate antibiotic therapy is crucial for improving the prognosis of CRO-BSI, regardless of the immune status.
- Published
- 2024
- Full Text
- View/download PDF
17. Diffuse skin findings secondary to lymph node tularemia in a patient with chronic rheumatoid arthritis on methotrexate
- Author
-
Kandemir, S, Dezoteux, F, Loiez, C, Hubiche, T, Laurent, S, and Darras, S
- Subjects
adenopathy ,case report ,immunosuppressed ,skin ,tularemia - Abstract
Tularemia has many atypical presentations which can represent a diagnostic challenge. The history is essential in the investigation of this disease. Bite-induced primary skin lesions should be distinguished from the infrequent immune-mediated secondary skin lesions. Herein, we present an atypical pseudovesicular rash secondary to Francisella tularensis.
- Published
- 2023
18. Impact of Immunosuppressed Status on Prognosis of Carbapenem-Resistant Organisms Bloodstream Infections.
- Author
-
Li, Yuan-Yuan, Chen, Yan, Li, Shan, An, Ran, Hu, Xiao-Yun, Jiang, Wei, Wang, Chun-Yao, Dong, Run, Yang, Qi-Wen, Weng, Li, Peng, Jin-Min, and Du, Bin
- Subjects
- *
LOGISTIC regression analysis , *PROPENSITY score matching , *PROGNOSIS , *IMMUNOCOMPROMISED patients ,MORTALITY risk factors - Abstract
Introduction: The impact of immunosuppression on prognosis of carbapenem-resistant organism (CRO) bloodstream infection (BSI) remains unclear. The aim of this study was to clarify the relationship between immunosuppression and mortality of CRO-BSI and to identify the risk factors associated with mortality in immunosuppressed patients. Methods: This retrospective study included 279 patients with CRO-BSI from January 2018 to March 2023. Clinical characteristics and outcomes were compared between the immunosuppressed and immunocompetent patients. The relationship between immunosuppression and 30-day mortality after BSI onset was assessed through logistic-regression analysis, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). Factors associated with mortality in immunosuppressed patients were analyzed using multivariable logistic regression analysis. Results: A total of 88 immunocompetent and 191 immunosuppressed patients were included, with 30-day all-cause mortality of 58.8%. Although the 30-day mortality in immunosuppressed patients was significantly higher than in immunocompetent patients (46.6% vs. 64.4%, P = 0.007), immunosuppression was not an independent risk factor for mortality in multivariate logistic regression analysis (odds ratio [OR] 3.53, 95% confidence interval [CI] 0.74–18.89; P = 0.123), PSM (OR 1.38, 95% CI 0.60–3.18; P = 0.449,) or IPTW (OR 1.40, 95% CI 0.58–3.36; P = 0.447). For patients with CRO-BSI, regardless of immune status, appropriate antibiotic therapy was associated with decreased 30-day mortality, while Charlson comorbidity index (CCI), intensive care unit (ICU)-acquired infection and thrombocytopenia at CRO-BSI onset were associated with increased mortality. Conclusion: Despite the high mortality rate of CRO-BSI, immunosuppression did not affect the mortality. Appropriate antibiotic therapy is crucial for improving the prognosis of CRO-BSI, regardless of the immune status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Changing respiratory pathogens infection patterns after COVID‐19 pandemic in Shanghai, China.
- Author
-
Wei, Muyun, Li, Shuangshuang, Lu, Xinhua, Hu, Kaiming, Li, Zhilan, and Li, Min
- Subjects
COVID-19 pandemic ,RESPIRATORY infections ,MYCOPLASMA pneumoniae infections ,RESPIRATORY syncytial virus ,MYCOPLASMA pneumoniae ,CORONAVIRUS diseases ,PARAINFLUENZA viruses - Abstract
To assess the positive rate of 11 respiratory pathogens in 2023, providing a comprehensive summary and analysis of the respiratory infection patterns after COVID‐19 pandemic. The study comprised 7544 inpatients suspected of respiratory infections who underwent respiratory pathogen multiplex polymerase chain reaction tests from July 2022 to December 31, 2023. We analyzed the positive rate of 11 pathogens over 18 months and the characterization of infection patterns among different age groups and immune states. Among 7544 patients (age range 4 months to 104 years, 44.99% female), the incidence of infected by at least one of the 11 pathogens was 26.07%. Children (55.18%, p < 0.05) experienced a significantly higher infection probability than adults (20.88%) and old (20.66%). Influenza A virus (8.63%), Mycoplasma pneumoniae (5.47%), and human rhinovirus (5.12%) were the most common pathogens. In children, M. pneumoniae (35.96%) replaced the predominant role of human respiratory syncytial virus (HRSV) (5.91%) in the pathogen spectrum. Age, immunosuppressed state, and respiratory chronic conditions were associated with a significantly higher risk of mixed infection. Immunosuppressed patients were more vulnerable to human coronavirus (4.64% vs. 1.65%, p < 0.05), human parainfluenza virus (3.46% vs. 1.69%, p < 0.05), and HRSV (2.27% vs. 0.55%, p < 0.05). Patterns in respiratory infections changed following regional epidemic control measures and the COVID‐19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Effect of Improved Nursing Strategy on Prognosis of Immunosuppressed Patients With Pneumonia and Sepsis: A Prospective Cohort Study.
- Author
-
Luo, Hongbo, Han, Wen, Zhang, Jiahui, Cheng, Wei, Li, Dongkai, Zhao, Mingxi, Cui, Na, and Zhu, Huadong
- Subjects
- *
PNEUMONIA treatment , *SEPSIS , *NURSING , *IMMUNOCOMPROMISED patients , *ARTIFICIAL respiration , *INTENSIVE care units - Abstract
Objectives: To investigate the effect of our improved nursing strategy on prognosis in immunosuppressed patients with pneumonia and sepsis. Methods: Immunosuppressed patients (absolute lymphocyte count <1000 cells/mm3) with pneumonia and sepsis were enrolled and divided into a control group and treatment group. The treatment group received the improved nursing strategy. The primary outcome in this study was 28-day mortality. Results: In accordance with the study criteria, 1019 patients were finally enrolled. Compared with patients in the control group, those in the treatment group had significantly fewer days on mechanical ventilation [5 (4, 7) versus 5 (4, 7) days, P =.03] and lower intensive care unit (ICU) mortality [21.1% (132 of 627) vs 28.8% (113 of 392); P =.005] and 28-day mortality [22.2% (139 of 627) vs 29.8% (117 of 392); P =.006]. The treatment group also had a shorter duration of ICU stay [9 (5, 15) vs 11 (6, 22) days, P =.0001] than the control group. The improved nursing strategy acted as an independent protective factor in 28-day mortality: odds ratio 0.645, 95% confidence interval: 0.449-0.927, P =.018. Conclusion: Our improved nursing strategy shortened the duration of mechanical ventilation and the ICU stay and decreased ICU mortality and 28-day mortality in immunosuppressed patients with pneumonia and sepsis. Trial registration: ChiCTR.org.cn, ChiCTR-ROC-17010750. Registered 28 February 2017. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Vaccinations in patients diagnosed with an autoimmune disorder receiving an immunosuppressive agent: a best practice implementation project.
- Author
-
Loflin, Betty, Upchurch, Linda, Palokas, Michelle, and Christian, Robin
- Subjects
- *
IMMUNIZATION , *MEDICAL protocols , *AUDITING , *HEALTH literacy , *IMMUNOSUPPRESSIVE agents , *HUMAN services programs , *PERSONNEL management , *DESCRIPTIVE statistics , *AUTOIMMUNE diseases , *CLINICAL competence , *EVIDENCE-based medicine , *HEALTH promotion , *EMPLOYEE attitudes - Abstract
Introduction: Immunosuppressed patients face increased health risks due to infections such as influenza or COVID-19. Scientific evidence supports improved health-related outcomes in this patient population, such as reduced hospitalizations, with up-to-date vaccinations. The project setting, a community-based rheumatology clinic, did not have a vaccination record specific to the needs of immunosuppressed patients, which may have led to suboptimal immunization status in these patients. Objective: This project aimed to promote evidence-based practices regarding the use of vaccinations in patients diagnosed with autoimmune disorders receiving immunosuppressive agents. Methods: This project used the JBI evidence implementation framework to promote best practices regarding vaccination. Two audit criteria were identified using a JBI evidence summary. Baseline audits identified gaps between the evidence and current practice. Barriers to best practice were then identified, and strategies implemented. Post-implementation audits measured changes in compliance. Results: Baseline audits revealed 67% compliance with the two best practices. Barriers included a lack of provider awareness of the current vaccination recommendations for immunosuppressed patients and a lack of customizable vaccine records. Strategies to address these barriers included educating providers about current national vaccination recommendations and implementing a new patient vaccination history intake form. Post-implementation audits revealed 83% compliance, a 16% increase from baseline. Conclusions: This evidence-based implementation project enhanced best practices by educating providers and implementing an updated patient vaccination history form. Recommendations included improved compliance with the use of the new form and assessing the effectiveness and usability of a customizable electronic form that interfaced with the clinic's electronic medical records. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series
- Author
-
José Pablo Díaz-Madriz, Esteban Zavaleta-Monestel, Carolina Rojas-Chinchilla, Sebastián Arguedas-Chacón, Bruno Serrano-Arias, Mery Alejandra Ferreto-Meza, Betzy María Romero-Chavarría, Priscila Zumbado-Amerling, Ana Fernanda Vásquez-Mendoza, Karla Sofia Gutiérrez-González, and César Rodríguez
- Subjects
Alkalihalobacillus clausii ,bacteremia ,probiotics ,immunosuppressed ,Specialties of internal medicine ,RC581-951 - Abstract
(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.
- Published
- 2023
- Full Text
- View/download PDF
23. Concomitant Serological and Molecular Methods for Strongyloides stercoralis Screening in an Endemic Area of Spain
- Author
-
Ana Lucas Dato, Philp Wikman-Jorgensen, Emilio Borrajo Brunete, María Dolores Hernández Rabadán, Hilarión García-Morante, María Adelino Merino Trigueros, José María Saugar Cruz, Elisa García-Vazquez, and Jara Llenas-García
- Subjects
Strongyloides ,screening ,migrants ,immunosuppressed ,serology ,stool PCR ,Medicine - Abstract
Strongyloidiasis is a widespread parasitic disease that can be life-threatening in immunosuppressed people. In the Mediterranean basin, autochthonous cases coexist with imported ones. We aimed to assess the utility of different screening methods, along with the frequency of strongyloidiasis and its associated risk factors in migrants and the native population. This cross-sectional study took place from 2019 to 2022 in the area of the Vega Baja Hospital in Alicante, Spain. Screening was performed in people who were immunosuppressed, at risk of immunosuppression, with blood asymptomatic eosinophilia, and in asymptomatic people from highly endemic countries. Screening methods were serological techniques (ELISA), stool parasitological tests (fecal concentration methods and agar plate culture), and a stool molecular test (PCR). Of the 168 participants (62.5% males, 53.0% migrants, 36.3% immunosuppressed, median age 57 years), 14 (8.3%) had confirmed strongyloidiasis, where 6 were confirmed by serology, 4 by PCR, and 4 by both methods. Overall, 9% of the migrants and 7.6% of the native-born patients were infected. Elevated IgE and hemoglobin and Latin American origin were associated with strongyloidiasis diagnosis. Screening with serology alone would have missed 28.6% of cases. We conclude that strongyloidiasis prevalence is high in our population, both in native and migrant groups, and stool PCR is a useful tool to increase case detection.
- Published
- 2024
- Full Text
- View/download PDF
24. Outcomes of initially nonoperative management of diverticulitis with abscess formation in immunosuppressed patients. DIPLICAB study COLLABORATIVE group.
- Author
-
Ocaña, Juan, García‐Pérez, Juan Carlos, Fernández‐Martínez, Daniel, Aguirre, Ignacio, Pascual, Isabel, Lora, Paola, Espin‐Basany, Eloy, Labalde‐Martínez, María, León, Carmen, Pastor‐Peinado, Paula, López‐Domínguez, Carlota, Muñoz‐Plaza, Nerea, Valle, Ainhoa, Dujovne, Paula, Alías, David, Pérez‐Santiago, Leticia, Correa, Alba, Carmona, María, Fernández‐Cebrián, José María, and Die, Javier
- Subjects
- *
DIVERTICULITIS , *PREOPERATIVE risk factors , *IMMUNOCOMPROMISED patients , *SURGICAL emergencies , *ABSCESSES , *BIOTHERAPY - Abstract
Aim: Management of diverticulitis with abscess formation in immunosuppressed patients (IMS) remains unclear. The main objective of the study was to assess short‐ and long‐term outcomes between IMS and immunocompetent patients (IC). The secondary aim was to identify risk factors for emergency surgery. Methods: A nationwide retrospective cohort study was performed at 29 Spanish referral centres between 2015–2019 including consecutive patients with first episode of diverticulitis classified as modified Hinchey Ib or II. IMS included immunosuppressive therapy, biologic therapy, malignant neoplasm with active chemotherapy and chronic steroid therapy. A multivariate analysis was performed to identify independent risk factors to emergency surgery in IMS. Results: A total of 1395 patients were included; 118 IMS and 1277 IC. There were no significant differences in emergency surgery between IMS and IC (19.5% and 13.5%, p = 0.075) but IMS was associated with higher mortality (15.1% vs. 0.6%, p < 0.001). Similar recurrent episodes were found between IMS and IC (28% vs. 28.2%, p = 0.963). Following multivariate analysis, immunosuppressive treatment, p = 0.002; OR: 3.35 (1.57–7.15), free gas bubbles, p < 0.001; OR: 2.91 (2.01–4.21), Hinchey II, p = 0.002; OR: 1.88 (1.26–2.83), use of morphine, p < 0.001; OR: 3.08 (1.98–4.80), abscess size ≥5 cm, p = 0.001; OR: 1.97 (1.33–2.93) and leucocytosis at third day, p < 0.001; OR: 1.001 (1.001–1.002) were independently associated with emergency surgery in IMS. Conclusion: Nonoperative management in IMS has been shown to be safe with similar treatment failure than IC. IMS presented higher mortality in emergency surgery and similar rate of recurrent diverticulitis than IC. Identifying risk factors to emergency surgery may anticipate emergency surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Drug monitoring during ciprofloxacin prophylaxis of allogeneic stem cell transplant patients: associations with bacterial infections through a monocentric observational prospective study.
- Author
-
Kaba, H.E.J., Hasenkamp, J., Tas, H., Schulz, M., Streit, F., Eiffert, H., Wulf, G., Truemper, L., Binder, L., Kaase, M., and Scheithauer, S.
- Abstract
Bacterial infection ranks amongst the most common causes of morbidity and mortality in patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT). Although ciprofloxacin (CIP) prophylaxis is recommended, information on serum levels and clinical course is lacking. To investigate relationships between CIP level and failure of prophylaxis, particularly in terms of whether different pharmacokinetic (PK) indices [area under the concentration–time curve (AUC 0–24h) vs single time samples] correlate differently with the outcome. This prospective observational monocentric study was conducted at a 1500-bed teaching hospital (March 2018–March 2019), including 63 adult patients with alloHSCT receiving CIP prophylaxis. Blood samples were drawn at three sampling times (1, 6 and 12 h post-administration), twice per week, and measured via high performance liquid chromatography. The onset of febrile episodes (FEBs) indicated suspected failure of CIP prophylaxis. Positive blood cultures [bloodstream infection (BSI)] indicated confirmed failure of prophylaxis. Seven of 63 patients died without significant differences in their average CIP levels compared with survivors, with patients experiencing FEBs (54/63) displaying a 13% [95% confidence interval (CI) 4–22%] lower probability of survival. In total, 225 sets of three values (triplets) were obtained from 58 primary CIP episodes. Triplets preceding BSI with Gram-negative bacteria (GNB-BSI) showed lower AUC 0–24h on average, but similar single time sample indices. An AUC 0–24h of ≤21.61 mgh/L resulted in four-fold higher odds of GNB-BSI (adjusted odds ratio 3.96, 95% CI 1.21–13.00). These results were independent of the administration route, patient demographics or sampling protocol deviations, indicating reduced CIP exposure upon GNB-BSI events. Monitoring CIP levels, using multiple sampling times, may be useful to reduce alloHSCT-associated bacterial infections. Further analysis is needed to investigate causality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Intrauterine devices are a safe form of contraception in users with solid organ transplantation: A single‐center experience.
- Author
-
Amaya, Stephanie I., Wolff, Sharon F., Ross, Meghan, and French, Valerie A.
- Abstract
Patients who undergo organ transplantation are advised to use contraception for health optimization, yet limited data exists on safe contraceptive options for this population. This study investigates the infection risk of intrauterine devices (IUDs) in patients who have received a solid organ transplant by evaluating the incidence of pelvic inflammatory disease (PID). We performed a retrospective chart review of subjects with a solid organ transplant who used an IUD between the years of January 2007 to February 2021. We included subjects ages 22–55 years at the time of IUD placement. We abstracted demographic information, transplant type, IUD type, immunosuppressive medications, screening for sexually transmitted infections, and diagnosis of PID. We identified 29 subjects that met the inclusion criteria. Six subjects had a copper IUD (21%) and 23 had a levonorgestrel IUD (79%). The most common organ transplanted was a kidney (
n = 10) and liver (n = 10) while five subjects had multiple organs transplanted. Twenty‐five (86.2%) subjects took immunosuppressive medications at the time of IUD insertion. Twenty‐four (82.8%) patients had their IUD placed after transplantation. The average time of IUD use was 2.5 years. . In our study of IUD use in patients with solid organ transplantation, no patients developed PID. IUDs are a safe contraceptive option for immunosuppressed transplant patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
27. Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series.
- Author
-
Díaz-Madriz, José Pablo, Zavaleta-Monestel, Esteban, Rojas-Chinchilla, Carolina, Arguedas-Chacón, Sebastián, Serrano-Arias, Bruno, Ferreto-Meza, Mery Alejandra, Romero-Chavarría, Betzy María, Zumbado-Amerling, Priscila, Vásquez-Mendoza, Ana Fernanda, Gutiérrez-González, Karla Sofia, and Rodríguez, César
- Subjects
- *
BACTEREMIA , *IMMUNOCOMPROMISED patients , *PROBIOTICS , *MICROBIOLOGY , *IMMUNOSUPPRESSION - Abstract
(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Rapid antimicrobial resistance detection methods for bloodstream infection in solid organ transplantation: Proposed clinical guidance, unmet needs, and future directions.
- Author
-
Turbett, Sarah E., Banach, David B., Bard, Jennifer Dien, Gandhi, Ronak G., Letourneau, Alyssa R., and Azar, Marwan M.
- Subjects
- *
DRUG resistance in microorganisms , *TRANSPLANTATION of organs, tissues, etc. , *MEDICAL microbiology , *DRUG resistance in bacteria , *ANTIMICROBIAL stewardship - Abstract
Recent advances in antimicrobial resistance detection have spurred the development of multiple assays that can accurately detect the presence of bacterial resistance from positive blood cultures, resulting in faster institution of effective antimicrobial therapy. Despite these advances, there are limited data regarding the use of these assays in solid organ transplant (SOT) recipients and there is little guidance on how to select, implement, and interpret them in clinical practice. We describe a practical approach to the implementation and interpretation of these assays in SOT recipients using the best available data and expert opinion. These findings were part of a consensus conference sponsored by the American Society of Transplantation held on December 7, 2021 and represent the collaboration between experts in transplant infectious diseases, pharmacy, antimicrobial and diagnostic stewardship, and clinical microbiology. Areas of unmet need and recommendations for future investigation are also presented. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory viruses within an acute oncology service improves patient care.
- Author
-
Beard, Kate R., Borca, Florina, Phan, Hang, Brown, Emma, Fenton, Paul A., Stansby, Jessica, Defty, John, and Clark, Tristan W.
- Abstract
COVID-19 has caused significant challenges for infection prevention measures and patient flow in hospital admission pathways. We aimed to assess the impact of replacing laboratory PCR with molecular point-of-care testing (mPOCT) for respiratory viruses including SARS-CoV-2, within an Acute Oncology Service (AOS). This pre- and post-implementation study took place in the AOS of a large teaching hospital, in Southampton, UK. We collected data from two periods: November 25th, 2019 to November 24th, 2020, when respiratory virus testing utilised laboratory PCR, and December 1st, 2020 to May 31st, 2021 following the introduction of mPOCT. The primary outcome was the time to results. 2189 patients were tested in the pre-implementation period and 1540 in the post implementation period. Median (IQR) time to results was 5.8 h (4.2–10.6) pre-implementation and 1.9 h (1.5–3.0) post-implementation (difference −3.6 h [95%CI to −3.8 to −3.5]; p < 0.0001). Median time spent in assessment areas was 6.0 h (4.1–7.9) pre-implementation and 5.5 h (3.8–7.4) post-implementation (p < 0.0001). 20 (0.9%) patients admitted via AOS assessment unit developed hospital-acquired respiratory virus infection pre-implementation versus 0 (0%) post-implementation (p = 0.031). Routine mPOCT for respiratory viruses, including SARS-CoV-2, was associated with a reduced time to results, reduced time in assessment areas, and a reduction in the rates of hospital-acquired respiratory virus infection in an acute oncology assessment unit. • Cancer patients are at high risk of poor outcomes with respiratory virus infections. • The first study assessing impact of point-of-care testing for viruses in an oncology unit. • Respiratory virus point-of-care testing yielded faster results than the laboratory. • Point-of-care testing was associated with improved patient flow through oncology unit. • Hospital acquired infection reduced following introduction of point-of-care testing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Invasive fungal sinusitis risk factors among immunosuppressed hematopoietic stem cell transplant recipients.
- Author
-
Munyemana, Marie‐Ange, Pande, Anupam, Kallogjeri, Dorina, Farrell, Nyssa F., Schneider, John S., Kendall, Peggy L., and Roland, Lauren T.
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *SINUSITIS , *PARAINFLUENZA viruses , *PARANASAL sinus diseases - Abstract
Key points: Invasive fungal sinusitis (IFS) rate and risk factors in transplant recipients were exploredIFS rate is higher in allogeneic recipients with prior transplants and worse comorbidity scoresThe at‐risk timeframes for IFS development were identified [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Actualización de las recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (COVID-19) en pacientes con trasplante renal
- Author
-
Verónica López, Auxiliadora Mazuecos, Florentino Villanego, María López-Oliva, Angel Alonso, Isabel Beneyto, Marta Crespo, Carmen Díaz-Corte, Antonio Franco, Francisco González-Roncero, Luis Guirado, Carlos Jiménez, Javier Juega, Santiago Llorente, Javier Paul, Alberto Rodríguez-Benot, Juan Carlos Ruiz, Ana Sánchez-Fructuoso, Vicente Torregrosa, Sofía Zárraga, Emilio Rodrigo, and Domingo Hernández
- Subjects
COVID-19 ,Kidney transplantation ,Immunosuppressed ,SARS-CoV-2 ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Resumen: La infección por el SARS-CoV-2 (COVID-19) ha supuesto un importante impacto en la actividad trasplantadora en nuestro país. Era esperable que la mortalidad y el riesgo de complicaciones asociadas a la COVID-19 en el receptor de trasplante renal (TR) fueran mayores debido a su condición de inmunosupresión y a las frecuentes comorbilidades asociadas. Desde el inicio de la pandemia en marzo del 2020 hemos mejorado rápidamente nuestro conocimiento acerca de la epidemiología, características clínicas y manejo de la COVID-19 postrasplante, redundando en un mejor pronóstico para nuestros pacientes. Las unidades de TR han sabido adaptar sus programas a esta nueva realidad, normalizándose la actividad tanto de donación como de trasplante en nuestro país.Este manuscrito presenta una propuesta de actualización de las recomendaciones generales para la prevención y el tratamiento de la infección en esta población tan vulnerable como son los receptores de un trasplante renal. Abstract: SARS-CoV-2 infection (COVID-19) has had a significant impact on transplant activity in our country. Mortality and the risk of complications associated with COVID-19 in kidney transplant (KT) recipients were expected to be higher due to their immunosuppressed condition and the frequent associated comorbidities. Since the beginning of the pandemic in March 2020 we have rapidly improved our knowledge about the epidemiology, clinical features and management of COVID-19 post-transplant, resulting in a better prognosis for our patients. KT units have been able to adapt their programs to this new reality, normalizing both donation and transplantation activity in our country.This manuscript presents a proposal to update the general recommendations for the prevention and treatment of infection in this highly vulnerable population such as KT.
- Published
- 2023
- Full Text
- View/download PDF
32. New Systemic Antifungal: Isavuconazole
- Author
-
Fong, I. W., Fong, I. W., Series Editor, and Fong, I.W.
- Published
- 2023
- Full Text
- View/download PDF
33. An Unresolving Case of Pyomyositis: A Case Report
- Author
-
Dhivakaran G
- Subjects
pyomyositis ,skeletal muscle ,immunosuppressed ,rare ,pulmonary tuberculosis ,Orthopedic surgery ,RD701-811 - Abstract
Pyomyositis which is also known as myositis tropicans is a rare condition where there is bacterial infection of the skeletal muscle. Its manifestation includes pain and tenderness of the affected muscle and general infective symptoms. It commonly occurs in immunocompromised individuals and patients with previous history of trauma to the affected muscle. We report a case of a 16-year-old boy with history of underlying bronchial asthma who presented with multiple abscesses. He underwent multiple operations to drain the infection and targeted antibiotic therapy subsequently. Despite undergoing surgical debridement, drainage and antibiotic treatment, he was still having repeated bouts of fever and his inflammatory markers were not reducing. He was then diagnosed with concurrent pulmonary tuberculosis infection which subjected him to an immunosuppressed state thus arising to the condition of pyomyositis and unresolving fever. The patient then made prompt improvement when the underlying cause of immunosuppression; pulmonary tuberculosis was treated as well.
- Published
- 2023
- Full Text
- View/download PDF
34. Hypoalbuminemia is a risk factor for invasive fungal infections and poor outcomes in infected kidney transplant recipients.
- Author
-
Santos, Angelie, Jorgenson, Margaret R., Osman, Fauzia, Srivastava, Aniruddha, Misch, Elizabeth Ann, Garg, Neetika, Aziz, Fahad, Swanson, Kurtis J., Mohamed, Maha, Djamali, Arjang, Mandelbrot, Didier, and Parajuli, Sandesh
- Subjects
- *
MYCOSES , *KIDNEY transplantation , *SERUM albumin , *BLASTOMYCOSIS , *HISTOPLASMOSIS , *IMMUNOSUPPRESSION - Abstract
Introduction: Invasive fungal infections (IFI), are estimated to occur in 2%–14% of kidney transplant recipients (KTRs) in the current era of immune suppression and are associated with high mortality rates. We hypothesized that hypoalbuminemia in KTRs is a risk factor for IFI and would be associated with poor outcomes. Methods: In this study, using data from a prospective cohort registry, we describe the frequency of IFI due to Blastomycosis, Coccidioidomycosis, Histoplasmosis, Aspergillosis, and Cryptococcus in KTRs with serum albumin levels measured 3–6 months before diagnosis. Controls were selected based on incidence density sampling. KTRs were divided into three groups based on the pre‐IFI serum albumin level: normal (≥4 g/dL), mild (3–4 g/dL), or severe (<3 g/dL) hypoalbuminemia. Outcomes of interest were uncensored graft failure after IFI and overall mortality. Results: A total of 113 KTRs with IFI were compared with 348 controls. The incidence rate of IFI among individuals with normal, mild, and severe hypoalbuminemia was 3.6, 8.7, and 29.3 per 100 person‐years, respectively. After adjustment for multiple variables, the trend for risk of uncensored graft failure following IFI was greater in KTRS with mild (HR = 2.1; 95% CI,.75–6.1) and severe (HR = 4.47; 95% CI, 1.56–12.8) hypoalbuminemia (P‐trend <.001) compared to those with normal serum albumin. Similarly, mortality was higher in severe hypoalbuminemia (HR = 1.9; 95% CI,.67–5.6) compared to normal serum albumin (P‐trend <.001). Conclusion: Hypoalbuminemia precedes the diagnosis of IFI in KTRs, and is associated with poor outcomes following IFI. Hypoalbuminemia may be a useful predictor of IFI in KTRs and could be incorporated into screening algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. The unique COVID‐19 experience in Western Australia: lessons learnt.
- Author
-
House, Caris L., Rawlins, Matthew, Dyer, John, Boan, Peter, and Musk, Michael
- Subjects
- *
INTENSIVE care units , *LENGTH of stay in hospitals , *COVID-19 , *IMMUNIZATION , *DEXAMETHASONE , *PATIENTS , *IMMUNOSUPPRESSION , *EXPERIENCE , *HOSPITAL admission & discharge , *SEVERITY of illness index , *TREATMENT effectiveness , *DESCRIPTIVE statistics ,MORTALITY risk factors - Abstract
Background: Western Australia (WA) was in a unique position to experience coronavirus disease 2019 (COVID‐19) in a highly vaccinated and geographically isolated population. Aim: To describe the COVID‐19 Omicron experience at the only quaternary hospital in WA following border opening from 3 March to 11 May 2022. Participants: A total of 158 adults with microbiologically confirmed COVID‐19 were admitted to the respiratory or intensive care unit (ICU). Outcomes: Admission numbers, disease severity, prevalence of COVID‐19 deterioration risk factors, immunisation status, severity of infection, immunosuppression and treatment regimen. Results: One hundred fifty‐eight COVID‐19–positive patients were admitted to the respiratory ward (n = 123) and the ICU (n = 35) during the study period. COVID‐19 infection was the primary admission reason in 32.9% of patients, 51.3% were male and the median age was 62 years. Aboriginal or Torres Strait Islanders (ATSI) were overrepresented (13.3%). Care was predominantly ward based (77.2%). Nearly half of the patients had mild COVID‐19 (49.4%). Dexamethasone was the most common treatment provided to patients (58.2%). The median length of stay was 5.8 days (interquartile range, 5–15). Eight patients died during the study period (5.1%), with three of those deaths attributable to COVID‐19. Conclusions: COVID‐19 case numbers following WA state border opening were of lower care acuity and disease severity than predicted. Two‐thirds of admissions were for other primary diagnoses, with incidental COVID detection. Hospital admissions were overrepresented by partially or unvaccinated patients and by ATSI Australians. An increase in social support along with general and geriatric medicine speciality input were required to treat hospitalised COVID‐19 cases in the WA Omicron wave. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Actualización de las recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (COVID-19) en pacientes con trasplante renal.
- Author
-
López, Verónica, Mazuecos, Auxiliadora, Villanego, Florentino, López-Oliva, María, Alonso, Angel, Beneyto, Isabel, Crespo, Marta, Díaz-Corte, Carmen, Franco, Antonio, González-Roncero, Francisco, Guirado, Luis, Jiménez, Carlos, Juega, Javier, Llorente, Santiago, Paul, Javier, Rodríguez-Benot, Alberto, Carlos Ruiz, Juan, Sánchez-Fructuoso, Ana, Torregrosa, Vicente, and Zárraga, Sofía
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
37. Vaccination in the Era of Immunosuppression.
- Author
-
Alnaimat, Fatima, Sweis, Jaleel Jerry G., Jansz, Jacqueline, Modi, Zeel, Prasad, Supritha, AbuHelal, Ayman, Vagts, Christen, Hanson, Hali A., Ascoli, Christian, Novak, Richard M., Papanikolaou, Ilias C., Rubinstein, Israel, and Sweiss, Nadera
- Subjects
VACCINE immunogenicity ,VACCINE effectiveness ,VACCINATION ,VACCINE safety ,SYSTEMIC lupus erythematosus - Abstract
Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) are at increased risk for severe infections. Vaccine responses and safety profiles may differ between AIIRD patients and the general population. While patients with autoimmune inflammatory rheumatic diseases (AIIRDs) often experience diminished humoral responses and reduced vaccine efficacy, factors such as the type of immunosuppressant medications used and the specific vaccine employed contribute to these outcomes. Notably, individuals undergoing B cell depletion therapy tend to have poor vaccine immunogenicity. However, despite these considerations, vaccine responses are generally considered clinically sufficient. Ideally, immunosuppressed AIIRD patients should receive vaccinations at least two weeks before commencing immunosuppressive treatment. However, it is common for many patients to already be on immunosuppressants during the immunization process. Vaccination rarely triggers flares in AIIRDs; if flares occur, they are typically mild. Despite the heightened infection risk, including COVID-19, among AIIRD patients with rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and other diseases on immunosuppressants, the vaccination rates remain suboptimal. The future directions of vaccination in the era of immunosuppression will likely involve customized vaccines with enhanced adjuvants and alternative delivery methods. By addressing the unique challenges faced by immunosuppressed individuals, we may improve vaccine efficacy, reduce the risk of infections, and ultimately enhance the health outcomes. Additionally, clinical trials to evaluate the safety and efficacy of temporarily discontinuing immunosuppressants during vaccination in various AIIRDs are crucial. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. British Transplantation Society/UKKA guidance on shingles vaccination.
- Author
-
Nimmo, Ailish, Mallindine, Charlotte, Morlidge, Clare, and Ravanan, Rommel
- Subjects
AGE distribution ,IMMUNOSUPPRESSION ,PATIENTS ,HERPES zoster ,HERPES zoster vaccines ,DRUG interactions ,MEDICAL referrals ,TRANSPLANTATION of organs, tissues, etc. ,DISEASE risk factors - Abstract
This article outlines the importance of the UK shingles vaccination programme and who is elgible for the vaccine [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
- Author
-
Gidari, Anna, Sabbatini, Samuele, Schiaroli, Elisabetta, Bastianelli, Sabrina, Pierucci, Sara, Busti, Chiara, Saraca, Lavinia Maria, Capogrossi, Luca, Pasticci, Maria Bruna, and Francisci, Daniela
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *FRACTIONS , *SARS-CoV-2 Omicron variant , *COVID-19 pandemic - Abstract
Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination. Methods: A Vero E6 cell-based infection assay was used to investigate the in vitro activity of the remdesivir–nirmatrelvir combination. The SARS-CoV-2 strains tested were 20A.EU1, BA.1 and BA.5. After incubation, a viability assay was performed. The supernatants were collected and used for viral titration. The Highest Single Agent (HSA) reference model was calculated. An HSA score >10 is considered synergic. Results: Remdesivir and nirmatrelvir showed synergistic activity at 48 and 72 h, with an HSA score of 52.8 and 28.6, respectively (p < 0.0001). These data were confirmed by performing supernatant titration and against the omicron variants: the combination reduced the viral titer better than the more active compound alone. An immunocompromised patient with prolonged and critical COVID-19 was successfully treated with remdesivir, nirmatrelvir/ritonavir, tixagevimab/cilgavimab and dexamethasone, with an excellent clinical–radiological response. However, she required further off-label prolonged therapy with nirmatrelvir/ritonavir until she tested negative. Conclusions: Remdesivir–nirmatrelvir combination has synergic activity in vitro. This combination may have a role in immunosuppressed patients with severe COVID-19 and prolonged viral shedding. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Clinical Manifestation of Cytomegalovirus-Associated Protein-Losing Enteropathy in Children.
- Author
-
Ferrua, Claire, Lemoine, Anais, Mosca, Alexis, and Lopes, Anne-Aurélie
- Abstract
In children, CMV-associated protein-losing enteropathy (PLE) is characterised by a benign course and spontaneous healing but can lead to generalised oedema. Poorly defined, it is diagnosed after unnecessary invasive tests. Children with CMV-associated PLE between 2009 and 2019 in two French hospitals are retrospectively described. Clinical and biological signs, CMV identification, endoscopy and histological findings, disease management and course are analysed. CMV-associated PLE is proven in 21 immunocompetent and 22 immunosuppressed patients, with ages consistent with primo-infection and reactivation, respectively. The digestive symptoms prevail in immunocompetent children, mainly with vomiting (85.7% versus 50%, CI [1.2; 39.2], p = 0.02). Immunocompetent patients show more oedema (61.9% versus 4.5%, CI [3.6; 1502.4], p < 0.001), linked to more severe hypoalbuminemia (21.2 g/L [17.6–25.7] versus 29.6 g/L [24.9–33.9], p = 0.01). A severe course is observed in 23.8% of the immunocompetent patients and 54.5% of the immunosuppressed ones (p = 0.06). Evidence of CMV infection based on non-invasive methods is found on 88.9% of immunocompetent and 95.5% of immunosuppressed patients (p = 0.58), while endoscopy was performed on 95.2% and 100% of them, respectively (p = 0.48), without any therapeutic change. Thus, CMV-associated PLE should be suspected in children with generalised oedema. Not as benign as previously described, it can be confirmed using non-invasive tests. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Necrotizing cutaneous zygomycosis by Saksenaea vasiformis in post-COVID-19 individual: A rare case report
- Author
-
S Prasanna, Mayuri Mahajan, Nikunja Kumar Das, and Nikhil Mahajan
- Subjects
cutaneous zygomycosis ,immunosuppressed ,post-covid-19 ,saksenaea vasiformis ,Medicine - Abstract
We report a rare case of cutaneous zygomycosis by Saksenaea vasiformis in post-COVID-19 individuals. A 55-year-old patient was COVID-19 positive and treated as per the protocols. Following recovery after 5 weeks, presents to the surgery outpatient department with complaints of slowly progressive cutaneous lesion developed into ulcerative lesion over the left lateral part of the abdomen, hip, and thigh. Based on histopathological and microbiological findings, he was diagnosed with as a case of cutaneous zygomycosis by S. vasiformis. Initially, conservative management with intravenous amphotericin B was given and followed by surgical debridement; later, the patient succumbed. In general, mucormycosis is associated with immunosuppression or debilitating diseases. The mode of entry for molds and spores of zygomycetes is through the respiratory tract through the nose and then reaches the sinuses, orbit, and intracranial structures. Hence, early clinical diagnosis, direct smears, and proper interventions lead to a good prognosis and reduced morbidity caused by zygomycosis. The therapeutic management of fungal infection is quite challenging; hence diagnosing zygomycosis at the earliest will be appropriate, especially in an immunocompromised state. The misusing of prophylactic drugs, steroids, and immunosuppressants for COVID-19 should be avoided and must be used as per protocol and guidelines.
- Published
- 2023
- Full Text
- View/download PDF
42. Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
- Author
-
Sachin Phakey, Sophie L. Rogers, Anthony J. Hall, and Lyndell L. Lim
- Subjects
Aciclovir ,Famciclovir ,Herpes zoster ,Immunocompromised ,Immunosuppressed ,Shingrix ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level of the Australian population. National prescription data for antivirals used to treat HZ may be used as a proxy for HZ incidence. We aimed to examine trends in antiviral prescriptions supplied for the treatment of HZ in Australia pre- and post-2016, and to assess whether Zostavax’s inclusion on the NIP correlated with a reduction in HZ antiviral prescription rates. Methods Using the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescribing data, we analysed antiviral prescriptions supplied for the treatment of HZ Australia-wide between 1994 and 2019. Annual prescription rates were calculated, and trends and changes in HZ antiviral use were explored descriptively and using Poisson models. Results HZ antiviral prescription rates increased 2.6-fold (160%) between 1995 and 2015 [25.4 (95% CI 25.2, 25.6) and 65.3 (95% CI 64.9, 65.6) prescriptions per 10,000 people, respectively], and then decreased 0.45-fold (55%) between 2016 and 2018 [60.9 (95% CI 60.6, 61.2) and 27.5 (95% CI 27.3, 27.9) prescriptions per 10,000 people, respectively]. The prescription rate for the antiviral famciclovir restricted specifically for treating HZ in immunocompromised individuals increased 8.5-fold (750%) between 2006 (year first listed) and 2019 [0.3 (95% CI 0.3, 0.3) and 2.5 (95% CI 2.4, 2.6) prescriptions per 10,000 people, respectively]. Conclusion The introduction of the live-attenuated HZ vaccine on Australia’s formal national vaccination program was associated with a reduction in HZ antiviral prescription rates within the Australian population. The data suggest that the introduction of Shingrix, the non-live subunit zoster vaccine, may also be associated with a similar reduction in HZ antiviral prescriptions used to treat the immunocompromised, as well as the general population, given its accepted greater efficacy over Zostavax.
- Published
- 2023
- Full Text
- View/download PDF
43. A case of central nervous system infection by Candida famata in an immunosuppressed patient with HIV-1 infection
- Author
-
Joao Caria, Ema Leal, Andre Dias, Helder Pinheiro, Diana Póvoas, and Fernando Maltez
- Subjects
Candida famata ,Central nervous system infection ,Immunosuppressed ,HIV ,Epidural abscess ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Invasive fungal infections caused by Candida species are increasingly observed in immunosuppressed patients. Candida albicans is the more often identified species and neurocandidiasis is associated with high mortality rates. Diagnosis and treatment of these infections are frequently challenging.We report a case of central nervous system infection caused by Candida famata in an HIV-1 infected patient.To our best knowledge this is just the second published case of neural infection by this agent.
- Published
- 2022
- Full Text
- View/download PDF
44. Acute Diverticulitis
- Author
-
Lanas, Angel, Latella, Giovanni, Tursi, Antonio, editor, Bafutto, Mauro, editor, Brandimarte, Giovanni, editor, and Chaves de Oliveira, Enio, editor
- Published
- 2022
- Full Text
- View/download PDF
45. TB Spine in Special Conditions
- Author
-
Mehta, Ankit I., Nico, Elsa, Dhatt, Sarvdeep Singh, editor, and Kumar, Vishal, editor
- Published
- 2022
- Full Text
- View/download PDF
46. Brain Abscess
- Author
-
DeRight, Jonathan and DeRight, Jonathan
- Published
- 2022
- Full Text
- View/download PDF
47. A Rare Case of Strongyloides stercoralis Hyperinfection in a Diabetic Patient from Romania—Case Report and Review of the Literature.
- Author
-
Costache, Carmen, Colosi, Ioana Alina, Neculicioiu, Vlad Sever, Florian, Diana Ioana, Petrushev, Bobe, Vasvari, Alexandra, and Seicean, Andrada
- Subjects
LITERATURE reviews ,HTLV ,PEOPLE with diabetes ,DUODENAL obstructions ,GASTRIC mucosa - Abstract
Severe cases of strongyloidiasis are most often associated with multiple causes of immune suppression, such as corticoid treatment and HTLV (human T-lymphotropic virus) coinfection. Diabetes is not traditionally considered a risk factor for the development of severe strongyloidiasis. We report a rare case of autochthonous severe strongyloidiasis in Romania, a European country with a temperate climate. A 71-year-old patient with no prior travel history was admitted with multiple gastrointestinal complaints and recent weight loss. CT (computed tomography) scans indicated duodenal wall thickening, and duodenal endoscopy evidenced mucosal inflammation, ulcerations and partial duodenal obstruction at D4. Microscopic examination of stool samples and biopsy specimens from the gastric and duodenal mucosa revealed an increased larval burden characteristic of Strongyloides stercoralis hyperinfection. Sequential treatment with albendazole and ivermectin achieved parasitological cure and complete recovery. The novelty of our case stems from the scarcity of severe strongyloidiasis cases reported in Europe and especially in Romania, the absence of other risk factors in our patient aside from diabetes, the involvement of the gastric mucosa and the rare presentation as partial duodenal obstruction. This case highlights the importance of considering strongyloidiasis as a differential diagnosis, even in temperate climates where cases are sporadic, in cases in which immune suppression is not evident and in the absence of eosinophilia. The case is presented in the context of the first literature review examining the relationship between severe strongyloidiasis and diabetes, emphasizing diabetes as a possible risk factor for severe strongyloidiasis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Molecular Alterations in Cutaneous Squamous Cell Carcinoma in Immunocompetent and Immunosuppressed Hosts—A Systematic Review.
- Author
-
Tsang, Denise Ann, Tam, Steve Y. C., and Oh, Choon Chiat
- Subjects
- *
IMMUNOCOMPETENCE , *GENETIC mutation , *GENETICS , *IMMUNOCOMPROMISED patients , *SYSTEMATIC reviews , *MOLECULAR biology , *GENE expression profiling , *TUMOR markers , *SQUAMOUS cell carcinoma , *EPIGENOMICS - Abstract
Simple Summary: Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer worldwide. Due to its high mutational burden, cSCC remains poorly understood at the molecular level. A considerable number of profiling studies have previously been performed on cSCC, but progress in the field has been slow due to the lack of consensus among these studies. Immunosuppressed patients (e.g. organ transplant recipients) are at greater risk of developing cSCC and this population experiences greater morbidity from this disease. In this study, we aim to review the molecular profile of cSCC among immunocompetent patients (ICPs) and immunosuppressed patients (ISPs) and to identify novel biomarkers of this disease. The molecular characterization of cSCC will shed new light on dysregulated pathways and potentially identify new key drivers of the disease, which may guide the direction of future targeted therapy in cSCC. The characterization of cutaneous squamous cell carcinoma (cSCC) at the molecular level is lacking in the current literature due to the high mutational burden of this disease. Immunosuppressed patients afflicted with cSCC experience considerable morbidity and mortality. In this article, we review the molecular profile of cSCC among the immunosuppressed and immunocompetent populations at the genetic, epigenetic, transcriptomic, and proteometabolomic levels, as well as describing key differences in the tumor immune microenvironment between these two populations. We feature novel biomarkers from the recent literature which may serve as potential targets for therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Gastrointestinal Histoplasmosis: A Descriptive Review, 2001–2021.
- Author
-
Ekeng, Bassey E., Itam-Eyo, Asa E., Osaigbovo, Iriagbonse I., Warris, Adilia, Oladele, Rita O., Bongomin, Felix, and Denning, David W.
- Subjects
- *
HIV infections , *HISTOPLASMOSIS , *HIV-positive persons , *SYMPTOMS , *ABDOMINAL pain - Abstract
Gastrointestinal histoplasmosis (GIH) is infrequently described in people without underlying HIV infection. We aimed to compare the clinical presentation of GIH in people with and without HIV infection. We conducted a literature search of published cases of GIH from 2001–2021 and found 212 cases. Of these, 142 (67.0%) were male, and 124 (58.5%) had HIV infection. Most cases were from North America (n = 88, 41.5%) and South America (n = 79, 37.3%). Of the 212 cases, 123 (58.0%) were included in both clinical and pathological analyses. The remainder were excluded as details about clinical and pathological findings were not available. Of the 123 cases, 41 had HIV infection while 82 were without HIV infection. The diagnosis was predominantly by histopathology (n = 109, 88.6%). A significant proportion of people with HIV infection had abdominal pain as the most predominant symptom of GIH compared to those without HIV infection (65.9% versus 41.9%, p < 0.05). The colon was the most affected site with a slightly higher proportion in those with HIV infection compared with cases without HIV infection (46.3% versus 42.7%). The commonest pathologic findings were caecal and ileal ulcers. Caecal ulcers were significantly more frequent in cases with HIV infection compared to those without HIV (32.1% versus 7.1%, p < 0.05). Despite being more common in people with HIV infection, GIH also affects people without HIV infection with similar clinical presentations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Toxoplasma gondii mimicking metastatic neoplasia in a senior indoor‐only cat.
- Author
-
Weng, Jennifer and Cridge, Harry
- Subjects
TOXOPLASMA gondii ,TUMORS ,PULMONARY nodules ,METASTASIS ,CLINDAMYCIN ,CYCLOSPORINE - Abstract
An 11‐year‐old cat presented for a 1‐week history of dyspnoea. The cat had a history of allergies that were being managed on cyclosporine. Physical examination revealed an increased respiratory rate and effort, and the cat was oxygen dependent. Thoracic radiographs revealed a severe diffuse nodular pulmonary pattern, suggestive of metastatic neoplasia. An abdominal ultrasound was performed to evaluate for a primary mass or evidence of disseminated disease. A 4.3 × 2.2 cm ileocolic mass was noted. Fine‐needle aspirates of the intestinal mass were poorly exfoliative. Toxoplasma gondii titres were performed (IgM <1:20 and IgG >1:20,480). Fine‐needle aspirates of the pulmonary nodules revealed neutrophilic and macrophagic inflammation with large numbers of 2–4 µm, crescent‐shaped organisms, consistent with Toxoplasma gondii. Cyclosporine was discontinued and clindamycin was prescribed. The cat was discharged 3 days later. Repeat imaging revealed resolution of the pulmonary and intestinal lesions. Clinical cure was achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.